Dr. Price has served as NeuroBo’s President and Chief Executive Officer since November 2021. Prior to joining NeuroBo, and since 2017, Dr. Price was Chief Medical Officer of the pharmacovigilance team of ProPharma Group, a global industry leader in comprehensive compliance services that span the entire lifecycle of pharmaceuticals, biologics, and devices. Previous to that, he served as Chief Executive Officer and Chief Medical Officer of Drug Safety Solutions, Inc., a provider of solutions for clinical and drug safety operations, from 2002 until its acquisition by ProPharma Group in 2017. From 1997 to 2002, Dr. Price was the Director of Clinical Development for Oncology at MedImmune, Inc., which is now the biologics subsidiary of AstraZeneca plc. Prior to joining MedImmune, Dr. Price worked in the contract research organization sector. Dr. Price began his pharmaceutical career at Glaxo Inc., (now GlaxoSmithKline plc) where he worked for nearly nine years in both the commercial and research divisions of that company.
From 2007 to 2016, Dr. Price served on the board of directors of Sarepta Therapeutics, Inc., a publicly traded commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases. Dr. Price is a clinical physician trained in internal medicine and is a former member of the American Medical Association, the Academy of Pharmaceutical Physicians and the American Society for Microbiology. Dr. Price received a B.A. from the University of Rio Grande and a M.D. from the University of Santiago.
Dr. Bartynski earned a B.S. in Chemical Engineering from Lehigh University and his Ph.D. in Chemical Engineering from the University of Southern California.
Dr. Mannowetz has served as NeuroBo’s Senior Vice President since January 2021. Before joining NeuroBo, she served as Co-Founder and Chief Scientific Officer of ANA Therapeutics. Before that, she was Co-Founder and Chief Scientific Officer of YourChoice Therapeutics, a Y Combinator backed startup, where she developed the fundamental technology for non-hormonal contraceptives. Earlier in her career, Dr. Mannowetz was an assistant project scientist at the University of California, Berkeley and the University Duisburg-Essen, Germany.
Dr. Mannowetz earned her Ph.D. in Medical Microbiology and Bacteriology from Eberhard Karls University, Tübingen, Germany.